Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Dedifferentiated Liposarcoma: early-phase trial registry
3 of 6 indexed Metastatic Dedifferentiated Liposarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Metastatic Dedifferentiated Liposarcoma: 6 US clinical trials tracked, 3 recruiting.
Metastatic Dedifferentiated Liposarcoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition metastatic-dedifferentiated-liposarcoma
OPEN 3 | RECR 50% | LATE 1 | EARLY 5 | RANK #2866 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Metastatic Dedifferentiated Liposarcoma lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Dedifferentiated Liposarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Dedifferentiated Liposarcoma is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Dedifferentiated Liposarcoma research.
National Cancer Institute (NCI) accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Dedifferentiated Liposarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 75 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Metastatic Dedifferentiated Liposarcoma research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
National Cancer Institute (NCI)
NCT06422806
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
NCT06498648
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
National Cancer Institute (NCI)
NCT05711615
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
Alliance for Clinical Trials in Oncology
NCT05694871
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
M.D. Anderson Cancer Center
NCT04668300
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
NCT05886634
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Dedifferentiated Liposarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Dedifferentiated Liposarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Dedifferentiated Liposarcoma page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Metastatic Dedifferentiated Liposarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Metastatic Dedifferentiated Liposarcoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Dedifferentiated Liposarcoma condition card totals 6 registered trials; most-linked intervention Computed Tomography; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.